Why Gum Therapy Works Differently Across Patients

The same periodontal treatment can produce different results—and genes are not yet the answer

Scaling and root planing can reduce periodontal pocket depth by about 1.4 mm at six months on average. That is meaningful progress in a chronic inflammatory disease, but an average conceals a familiar clinical reality: some patients stabilize after non-surgical treatment, while others need further treatment. Researchers increasingly ask whether differences in the subgingival microbiome, inflammatory signaling, or inherited genetics explain that gap.

The strongest answer so far is microbiological and clinical, not genetic. Mechanical periodontal therapy disrupts a disease-associated biofilm and reduces the bacterial burden beneath the gumline. Cytokine-related genetic variants offer a plausible explanation for some variation in inflammation and treatment response, but genotype-guided periodontal care remains a hypothesis rather than a validated clinical tool.

Scaling changes an ecosystem, not merely a dirty tooth surface

Periodontitis involves a dense microbial community living below the gumline alongside a host immune response that can damage the tissues meant to contain it. Scaling and root planing, the core form of non-surgical periodontal therapy, mechanically removes calculus and disrupts that biofilm. The goal is not sterilization; mouths are ecosystems, and a sterile one would be a strange place to aim. The goal is to reduce disease-associated organisms and create conditions more compatible with periodontal health.

A 2024 systematic review by Laforgia et al. describes this process as a shift away from periodontal pathogens and toward health-compatible commensal organisms. It also identifies IL-1β, IL-6, and TNF-α as central inflammatory mediators in periodontitis. These cytokines can help sustain dysbiosis: inflammation changes the local environment in ways that favor harmful microbes, which can then perpetuate inflammation.

The clinical benchmark remains modest but reproducible. A 2025 review of probiotics alongside non-surgical therapy reports a mean probing-depth reduction of approximately 1.4 mm after six months of scaling and root planing alone. Probing depth is a standard clinical measure, not a direct measure of long-term tooth retention, but it tracks a feature of disease that clinicians need to control. A 1.4 mm average also leaves room for uneven individual responses.

The microbiome shift has longitudinal support

Two recent studies make the ecological argument more concrete. Li et al. (2025) examined microbiome outcomes after non-surgical periodontal therapy combined with an intensive antiplaque regimen. The study found treatment-associated decreases in disease-associated species, while also asking whether different antiplaque protocols change the size of that shift. The available findings support a real post-treatment change, but they do not settle how much any particular home-care protocol adds.

Johnston et al. (2023) followed subgingival biofilm composition over time after periodontal treatment with hand and ultrasonic instruments. Its time-series design matters. A single before-and-after sample can show suppression immediately after treatment; repeated sampling can better test whether the microbial community changes across follow-up. Together, these studies support the conclusion that mechanical therapy produces more than a short-lived reduction in plaque.

Still, microbiome measurements do not yet tell a clinician exactly which treatment an individual patient should receive. They describe composition and associations, not a complete causal map. Smoking, daily plaque control, diabetes, pocket anatomy, treatment technique, and maintenance care can all plausibly affect outcomes. The current literature has not formally separated how much of the remaining variation belongs to each factor.

Why genetics is compelling—and why it remains unproven

Genetics has an intuitive appeal here. If inherited variants affect cytokines such as IL-1β, IL-6, or TNF-α, they could alter the intensity or persistence of inflammation after biofilm disruption. The Laforgia review links cytokine gene polymorphisms to disease severity and variation in treatment response at a mechanistic level. That is biologically coherent, but coherence is not a treatment algorithm.

No study described here reports extractable clinical effect estimates showing that a specific IL-1, TNF-α, or matrix metalloproteinase variant predicts who will respond to scaling and root planing. There are no genotype-stratified randomized trials showing that one periodontal treatment works better than another for carriers of a particular variant. Nor do the available microbiome studies report whether genetically higher-risk patients clear organisms such as Porphyromonas gingivalis, Treponema denticola, or Tannerella forsythia more slowly after treatment.

A five-year cohort study by LaMonte et al. (2021) offers an important counterweight. In postmenopausal women, baseline subgingival microbiome composition was associated with alveolar bone loss measured five years later. The endpoint was radiographic bone loss, a clinically meaningful hard outcome, but the study was observational and did not test treatment response. It cannot prove that changing a baseline microbial signature prevents bone loss. It does show that microbial information alone can carry prognostic value without genetic covariates.

That finding weakens the claim that genetic profiling is necessary for personalized periodontal care. Genetics may still add information, but nobody has quantified its incremental predictive value above microbial, behavioral, and clinical data. A consumer genetic test cannot currently tell a patient whether scaling will work or which probiotic to buy.

Probiotics may help, but restoration claims outrun the evidence

Probiotics are the best-studied adjunct in this group of therapies. A 2022 systematic review and meta-analysis by Gheisary et al. found that probiotic supplementation improved gingival index and related clinical, microbiological, and immunological measures in periodontal disease. Proposed mechanisms include competition with pathogens, production of bacteriocins and organic acids, and reduced inflammatory signaling. Those mechanisms are plausible; they do not establish that every strain, dose, or delivery method produces the same clinical effect.

A 2024 systematic review comparing probiotics with antibiotics describes probiotics as promising adjuncts and potential alternatives where antibiotic resistance is a concern. That language is appropriately restrained. Probiotics have not displaced scaling and root planing, and the evidence does not justify treating them as equivalent to standard periodontal treatment.

There is also a reason to resist the word "restore." A 2024 systematic review of probiotics after antibiotic-related microbiome disruption concluded that their ability to prevent or reverse disruption remains uncertain and that claims of restoring a microbiome to its pre-antibiotic state may be overstated. This review studied antibiotic exposure rather than periodontal therapy, so it does not directly refute probiotics after scaling. It does challenge broad claims that probiotics reliably normalize any disturbed microbial ecosystem.

Natural-product adjuncts show a similar early pattern. A 2026 systematic review and meta-analysis by Molon et al. reported improved periodontal clinical parameters after non-surgical treatment, but effects in this category are generally small to moderate and trials vary substantially. Such therapies may merit study as add-ons, not replacement therapy.

What patients can act on now

For active periodontitis, the evidence supports prompt professional evaluation and scaling and root planing when indicated. Mechanical treatment has the clearest record for reducing subgingival disease burden and improving probing depth. It also addresses a plausible source of persistent inflammatory signaling, although periodontal treatment should not be marketed as a proven cure for systemic disease.

• Use probiotics, if at all, as an adjunct with modest expectations rather than as a substitute for periodontal care.
• Do not use cytokine-polymorphism testing to choose periodontal treatment; clinical validation is missing.
• Expect future research to matter most if it tests predefined genetic groups, tracks post-treatment microbial clearance, and measures outcomes that patients feel or keep teeth over—not only biomarkers.

The personalized-periodontics story may eventually include genetics. Today, the actionable science is simpler: disrupt the disease-associated biofilm, maintain the result, and treat genetic predictions as unfinished research.